AJP - Regu Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 265: R834-R839, 1993;
0363-6119/93 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamori, T.
Right arrow Articles by Murakami, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamori, T.
Right arrow Articles by Murakami, N.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 265, Issue 4 834-R839, Copyright © 1993 by American Physiological Society


ARTICLES

Effect of a central CRF antagonist on cardiovascular and thermoregulatory responses induced by stress or IL-1 beta

T. Nakamori, A. Morimoto and N. Murakami
Department of Physiology, Yamaguchi University School of Medicine, Japan.

We investigated the role of central corticotropin-releasing factor (CRF) in the development of cardiovascular and thermal responses induced by stress or by interleukin-1 beta (IL-1 beta) in free-moving rats. Intracerebroventricular (icv) injection of alpha-helical CRF9-41 (10 micrograms), a CRF receptor antagonist, significantly attenuated hypertension, tachycardia, and a rise in body temperature induced by cage-switch stress, a mild stress. However, icv injection of alpha-helical CRF9-41 (10 micrograms) had no effect on hypertension, tachycardia, or fever induced by intraperitoneal (ip) injection of IL-1 beta (2 micrograms/kg) or icv prostaglandin E2 (PGE2, 100 ng). In contrast, icv injection of alpha-helical CRF9-41 (10 micrograms) significantly attenuated hypertension, tachycardia, or fever induced by icv injection of IL-1 beta (20 ng). The present results suggest that central CRF has an important role in the development of the cage-switch stress-induced responses, but it does not seem to contribute to the hypertension, tachycardia, and fever induced by ip IL-1 beta or by central PGE2. However, it is possible that when IL-1 beta directly acts on the central nervous system, some of its actions are mediated by central CRF.


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. L. Lee, R. C. Webb, and M. W. Brands
Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1394 - R1398.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
Z.-H. Zhang, S.-G. Wei, J. Francis, and R. B. Felder
Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R916 - R927.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
T. Oka, K. Oka, and T. Hori
Mechanisms and Mediators of Psychological Stress-Induced Rise in Core Temperature
Psychosom Med, May 1, 2001; 63(3): 476 - 486.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Watanabe, Y. Sakata, T. Fujioka, D. Sadamitsu, and T. Maekawa
Glucocorticoid Enhances Interleukin-1-Induced Pressor Response in Freely Moving Rats Through Its Effect on Nitric Oxide Release
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 24 - 30.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Watanabe, Y. Saiki, and Y. Sakata
The Effect of Central Angiotensin II Receptor Blockade on Interleukin-1beta - and Prostaglandin E-Induced Fevers in Rats: Possible Involvement of Brain Angiotensin II Receptor in Fever Induction
J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 873 - 881.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online